Poly-L-lysine hydrobromide (MW 30000-70000)

Name: Poly-L-lysine hydrobromide (MW 30000-70000)
Brand: MedChemExpress
SKU: HY-126437
Rating: 4.5 (1 reviews)

Art. -Nr.: HY-126437: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

Poly-L-lysine hydrobromide (MW 30000-70000) is a water-soluble synthetic polypeptide. Poly-L-lysine hydrobromide (MW 30000-70000) downregulates Bcl-2 and upregulates Bax and p53 proteins. Poly-L-lysine hydrobromide (MW 30000-70000) promotes Apoptosis and reduces VEGF expression. Poly-L-lysine hydrobromide (MW 30000-70000) shows anticancer activity against a variety of tumors. Poly-L-lysine hydrobromide (MW 30000-70000) can also be used as a coating material.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

Poly-L-lysine hydrobromide (MW 30000-70000) Chemische Struktur

CAS. Nr. : 25988-63-0

Größe	Verfügbarkeit	Menge
5 mg	Auf Lager	Estimated Time of Arrival: December 31
10 mg	Auf Lager	Estimated Time of Arrival: December 31
50 mg	Angebot einholen
100 mg	Angebot einholen

or Massenanfrage

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

This product is a controlled substance and not for sale in your territory.

Kundenbewertung

Based on 1 publication(s) in Google Scholar

Other Forms of Poly-L-lysine hydrobromide (MW 30000-70000):

Poly-L-lysine hydrochloride In-stock
Poly-L-lysine hydrobromide (MW 70000-150000) In-stock
Poly-L-lysine hydrobromide (MW 150000-300000) In-stock
Poly-L-lysine hydrobromide (MW ＞300000) In-stock
Poly-L-lysine hydrobromide (MW 15000-30000) In-stock
Poly-L-lysine hydrobromide (MW 4000-15000) In-stock
Poly-L-lysine hydrobromide (MW 1000-5000) In-stock
Poly-L-lysine solution (0.01%, sterile-filtered, MW 150000-300000) In-stock

1 Publications Citing Use of MCE Poly-L-lysine hydrobromide (MW 30000-70000)

•Sci Adv. 2023 Jun 2;9(22):eadg3365. [Abstract]

Spezialitätsempfehlungen

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Alle Bcl-2 Family Isoform-spezifische Produkte anzeigen:

Alle Isoformen anzeigen

Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim BNIP3 Bad

Alle VEGFR Isoform-spezifische Produkte anzeigen:

Alle Isoformen anzeigen

VEGFR1/Flt-1 VEGFR2/KDR/Flk-1 VEGFR3/Flt-4

Biologische Aktivität
Reinheit & Dokumentation
Verweise
Kundenbewertung

Beschreibung

IC₅₀ & Target^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8]

Bax

Bcl-2

In Vitro

Poly-L-lysine hydrobromide (MW 30000-70000) ( 0.1-25 µg/mL, 24 h) shows anti-proliferative activities against human cancer cells, with IC₅₀ values of 3.36 µM, 8.23 µM, 3.53 µM and 6.04 µM for K562, A549, U937, and B16F10 cells respectively^[2].
Poly-L-lysine hydrobromide (MW 30000-70000) (0.5-40 µg/mL, 48 h) shows antiproliferative activity in MCF-7 cells (an IC₅₀ value of 4.22 µg/mL)^[3].
Poly-L-lysine hydrobromide (MW 30000-70000) (0.5-30.0 μg/mL, 24-72 h) decreases cell proliferation in in-vitro HUVECs and DAL cells, with alteration in cellular morphology in DAL cells^[4].
Poly-L-lysine hydrobromide (MW 30000-70000) (0-200 μg/mL) stimulates arachidonic acid release in cultures of 3T3 Swiss mouse fibroblasts biosynthetically labeled with [³H]arachidonic acid^[5].
Poly-L-lysine hydrobromide (MW 30000-70000) (at the working pH, isoelectric point ∼10.5)/heparin multilayer coatings prevent blood protein adsorption^[6].
Poly-L-lysine hydrobromide (MW 30000-70000) (1.0-40.0 μg/mL, 48 h) inhibits the proliferation of MDA-MB-231 and B16F10 cancer cells^[7].
Poly-L-lysine hydrobromide (MW 30000-70000) (10-120 μg/mL, 2-4 h) dose-dependently decreases viability of HeLa cells^[8].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[2]

Cell Line:	K562, A549, U937, and B16F10 cells
Concentration:	0.1, 0.5,1, 5, 10, 20, 25 µg/mL
Incubation Time:	24 h
Result:	Showed anti-proliferative activities in cancers cells (K562, A549, U937, and B16F10). Was the most potent in K562 cells.

In Vivo

Poly-L-lysine hydrobromide (MW 30000-70000) (20-40mg/kg, i.p., 14 days) inhibits Ehrlich Ascites Carcinoma (EAC), with apoptosis of EAC cells in mice^[2].
Poly-L-lysine hydrobromide (MW 30000-70000) (20-40mg/kg, i.p., 21 days) inhibits sarcoma-180 solid tumor in Swiss female albino mice^[2].
Poly-L-lysine hydrobromide (MW 30000-70000) (20-40mg/kg, i.p., starts 10 days after tumor inoculations and was continued for 21 days) inhibits DAL solid tumor growth in mice^[4].
Poly-L-lysine hydrobromide (MW 30000-70000) (20-40mg/kg, i.p., starts 10 days after tumor inoculations and was continued for 21 days) induces apoptosis in 2D and 3D tumor microenvironment of both MDA-MB-231 and B16F10 induced mice model^[7].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	EAC tumor bearing mouse (inoculated with 0.1 ml of tumor cell suspension, prepared in phosphate buffer solution containing 2×10⁶ cells/mL)^[2]
Dosage:	20, 40 mg/kg
Administration:	Intraperitoneal injection (i.p.), 14 days
Result:	Reduced the ascite fluid volume, packed cell volume and viable tumor cell count, whereas, increased non-viable tumor cell count in a dose dependent manner. Increased the hemoglobin counts towards the normal levels. Showed chromatin condensation, blebbing of plasma membrane, irregularity in cell morphology (EAC). Inhibited peritoneal angiogenesis. Showed apoptosis of EAC cells.

Animal Model:	Sarcoma-180 solid tumor model (given subcutaneous inoculation (s.c.) of 0.1 ml sarcoma-180 cell suspension containing 2×10⁶ cells/mL)^[2]
Dosage:	20, 40 mg/kg
Administration:	Intraperitoneal injection (i.p.), 21 days
Result:	Inhibited tumor growth. Could bring down the WBC level compare to Sarcoma-180 control group. Enhanced the survival of sarcoma-180 bearing mice. Showed less proliferation and muscle invasion in extents areas of coagulative necrosis. Induced cell apoptosis by triggering the expression of p53 and Bcl-2.

Molekulargewicht

30000-70000

Formel

C₈H₁₉BrN₂O

CAS. Nr.

25988-63-0

Appearance

Solid

Color

White to off-white

SMILES

CN[C@@H](CCCC[NH3+])C(C)=O.[n].[Br-].[n]

Versand

Room temperature in continental US; may vary elsewhere.

Speicherung

-20°C, protect from light, stored under nitrogen

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

Lösungsmittel & Löslichkeit

In Vitro:

H₂O : 100 mg/mL (Need ultrasonic)

Molaritätsrechner
Verdünnungsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Reinheit & Dokumentation

Select Batch:

Data Sheet (279 KB) SDS (393 KB)

COA (246 KB)

Handling Instructions (2659 KB)

Verweise

[1]. Archishman Ghosh, et al. Three archetypical classes of macromolecular regulators of protein liquid-liquid phase separation. Proc Natl Acad Sci U S A. 2019;116(39):19474-19483. [Content Brief]

[2]. Debnath S, et al. Poly-L-Lysine Inhibits Tumor Angiogenesis and Induces Apoptosis in Ehrlich Ascites Carcinoma and in Sarcoma S-180 Tumor. Asian Pac J Cancer Prev. 2017 Aug 27;18(8):2255-2268. [Content Brief]

[3]. Mukherjee A, et al. DNA interactive property of poly-L-lysine induces apoptosis in MCF-7 cells through DNA interaction. J Biochem Mol Toxicol. 2023 Aug;37(8):e23378. [Content Brief]

[4]. Debnath S, et al. Induction of apoptosis, anti-proliferation, tumor-angiogenic suppression and down-regulation of Dalton's Ascitic Lymphoma (DAL) induced tumorigenesis by poly-l-lysine: A mechanistic study. Biomed Pharmacother. 2018 Jun;102:1064-1076. [Content Brief]

[5]. Shier WT, et al. Polycations as prostaglandin synthesis inducers. Stimulation of arachidonic acid release and prostaglandin synthesis in cultured fibroblasts by poly(L-lysine) and other synthetic polycations. Biochim Biophys Acta. 1984 Apr 18;793(2):238-50. [Content Brief]

[6]. Barrantes A, et al. Poly-l-lysine/heparin multilayer coatings prevent blood protein adsorption. J Colloid Interface Sci. 2017 Jan 1;485:288-295. [Content Brief]

[7]. Debnath S, et al. Poly-l-Lysine inhibits VEGF and c-Myc mediated tumor-angiogenesis and induces apoptosis in 2D and 3D tumor microenvironment of both MDA-MB-231 and B16F10 induced mice model. Int J Biol Macromol. 2021 Jul 31;183:528-548. [Content Brief]

[8]. Lin CW, et al. Protective role of autophagy in branched polyethylenimine (25K)- and poly(L-lysine) (30-70K)-induced cell death. Eur J Pharm Sci. 2012 Dec 18;47(5):865-74. [Content Brief]